LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 24

Search options

  1. Article: Identification of Rare Damaging Missense and Loss of Function Variants in GWAS Loci Using Genome Sequencing Data from Two Cohorts of Familial Late-Onset Alzheimer's Disease.

    Gunasekaran, Tamil Iniyan / Reyes-Dumeyer, Dolly / Faber, Kelley M / Goate, Alison / Boeve, Brad / Cruchaga, Carlos / Pericak-Vance, Margaret / Haines, Jonathan L / Rosenberg, Roger / Tsuang, Debby / Mejia, Diones Rivera / Medrano, Martin / Lantigua, Rafael A / Sweet, Robert A / Bennett, David A / Wilson, Robert S / Foroud, Tatiana / Vardarajan, Badri N / Mayeux, Richard

    medRxiv : the preprint server for health sciences

    2023  

    Abstract: Purpose: Few rare pathogenic variants have been identified in the 70+ genetic loci from genome wide association studies of late-onset Alzheimer's disease (AD), limiting research on underlying mechanisms, risk assessment, and genetic counseling.: ... ...

    Abstract Purpose: Few rare pathogenic variants have been identified in the 70+ genetic loci from genome wide association studies of late-onset Alzheimer's disease (AD), limiting research on underlying mechanisms, risk assessment, and genetic counseling.
    Methods: Using genome sequencing data from 197 families in The National Institute on Aging Alzheimer's Disease Family Based Study (AD-FBS), and 214 families in The Estudio Familiar de la Influencia Genética en Alzheimer (EFIGA), we characterized rare coding variants predicted to highly damaging missense or loss of function variants (LoF) within known GWAS loci.
    Results: Eight coding and one LoF variant segregated in 10 (5.1%) AD-FBS families and 16 coding and two LoF variants segregated in 18 (8.4%) EFIGA families.
    Conclusions: Although rare variants were found in both family groups, many families had no gene variant segregating within the family, indicating that the genetic basis for AD has yet to be fully defined.
    Language English
    Publishing date 2023-12-18
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.12.18.23300145
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort.

    Nudelman, Kelly N H / Lin, Jue / Lane, Kathleen A / Nho, Kwangsik / Kim, Sungeun / Faber, Kelley M / Risacher, Shannon L / Foroud, Tatiana M / Gao, Sujuan / Davis, Justin W / Weiner, Michael W / Saykin, Andrew J

    Journal of Alzheimer's disease : JAD

    2019  Volume 71, Issue 1, Page(s) 33–43

    Abstract: Background: Although shorter telomeres have been associated with Alzheimer's disease (AD), it is unclear whether longitudinal change in telomere length is associated with AD progression.: Objective: To investigate the association of telomere length ... ...

    Abstract Background: Although shorter telomeres have been associated with Alzheimer's disease (AD), it is unclear whether longitudinal change in telomere length is associated with AD progression.
    Objective: To investigate the association of telomere length change with AD diagnosis and progression.
    Methods: In 653 individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, T/S ratio (telomere versus single copy gene), a proxy of telomere length, was measured for up to five visits per participant (N = 1918 samples post-QC) using quantitative PCR (qPCR). T/S ratio was adjusted for batch effects and DNA storage time. A mixed effects model was used to evaluate association of telomere length with AD diagnostic group and interaction of age and diagnosis. Another mixed effects model was used to compare T/S ratio changes pre- to post-conversion to MCI or AD to telomere change in participants with stable diagnoses.
    Results: Shorter telomeres were associated with older age (Effect Size (ES) = -0.23) and male sex (ES = -0.26). Neither baseline T/S ratio (ES = -0.036) nor T/S ratio change (ES = 0.046) differed significantly between AD diagnostic groups. MCI/AD converters showed greater, but non-significant, telomere shortening compared to non-converters (ES = -0.186).
    Conclusions: Although AD compared to controls showed small, non-significant effects for baseline T/S ratio and T/S ratio shortening, we did observe a larger, though still non-significant effect for greater telomere shortening in converters compared to non-converters. Although our results do not support telomere shortening as a robust biomarker of AD progression, further investigation in larger samples and for subgroups of participants may be informative.
    MeSH term(s) Age Factors ; Aged ; Alzheimer Disease/diagnosis ; Alzheimer Disease/genetics ; Databases, Factual ; Disease Progression ; Female ; Humans ; Male ; Neuroimaging/methods ; Sex Factors ; Telomere Homeostasis/physiology ; Telomere Shortening
    Language English
    Publishing date 2019-07-17
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-190010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.

    Nho, Kwangsik / Nudelman, Kelly / Allen, Mariet / Hodges, Angela / Kim, Sungeun / Risacher, Shannon L / Apostolova, Liana G / Lin, Kuang / Lunnon, Katie / Wang, Xue / Burgess, Jeremy D / Ertekin-Taner, Nilüfer / Petersen, Ronald C / Wang, Lisu / Qi, Zhenhao / He, Aiqing / Neuhaus, Isaac / Patel, Vishal / Foroud, Tatiana /
    Faber, Kelley M / Lovestone, Simon / Simmons, Andrew / Weiner, Michael W / Saykin, Andrew J

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2020  Volume 16, Issue 9, Page(s) 1213–1223

    Abstract: Introduction: Abnormal gene expression patterns may contribute to the onset and progression of late-onset Alzheimer's disease (LOAD).: Methods: We performed transcriptome-wide meta-analysis (N = 1440) of blood-based microarray gene expression ... ...

    Abstract Introduction: Abnormal gene expression patterns may contribute to the onset and progression of late-onset Alzheimer's disease (LOAD).
    Methods: We performed transcriptome-wide meta-analysis (N = 1440) of blood-based microarray gene expression profiles as well as neuroimaging and cerebrospinal fluid (CSF) endophenotype analysis.
    Results: We identified and replicated five genes (CREB5, CD46, TMBIM6, IRAK3, and RPAIN) as significantly dysregulated in LOAD. The most significantly altered gene, CREB5, was also associated with brain atrophy and increased amyloid beta (Aβ) accumulation, especially in the entorhinal cortex region. cis-expression quantitative trait loci mapping analysis of CREB5 detected five significant associations (P < 5 × 10
    Discussion: RNA from peripheral blood indicated a differential gene expression pattern in LOAD. Genes identified have been implicated in biological processes relevant to Alzheimer's disease. CREB, in particular, plays a key role in nervous system development, cell survival, plasticity, and learning and memory.
    MeSH term(s) Aged ; Alzheimer Disease/blood ; Alzheimer Disease/genetics ; Alzheimer Disease/pathology ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloid beta-Peptides/metabolism ; Aniline Compounds ; Atrophy/pathology ; Brain/pathology ; Cyclic AMP Response Element-Binding Protein A/genetics ; Entorhinal Cortex/pathology ; Ethylene Glycols ; Female ; Gene Expression Profiling ; Genotyping Techniques ; Humans ; Male ; Positron-Emission Tomography
    Chemical Substances Amyloid beta-Peptides ; Aniline Compounds ; CREB5 protein, human ; Cyclic AMP Response Element-Binding Protein A ; Ethylene Glycols ; florbetapir (6867Q6IKOD)
    Language English
    Publishing date 2020-08-05
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.12092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.

    Dage, Jeffrey L / Eloyan, Ani / Thangarajah, Maryanne / Hammers, Dustin B / Fagan, Anne M / Gray, Julia D / Schindler, Suzanne E / Snoddy, Casey / Nudelman, Kelly N H / Faber, Kelley M / Foroud, Tatiana / Aisen, Paul / Griffin, Percy / Grinberg, Lea T / Iaccarino, Leonardo / Kirby, Kala / Kramer, Joel / Koeppe, Robert / Kukull, Walter A /
    La Joie, Renaud / Mundada, Nidhi S / Murray, Melissa E / Rumbaugh, Malia / Soleimani-Meigooni, David N / Toga, Arthur W / Touroutoglou, Alexandra / Vemuri, Prashanthi / Atri, Alireza / Beckett, Laurel A / Day, Gregory S / Graff-Radford, Neill R / Duara, Ranjan / Honig, Lawrence S / Jones, David T / Masdeu, Joseph C / Mendez, Mario F / Musiek, Erik / Onyike, Chiadi U / Riddle, Meghan / Rogalski, Emily / Salloway, Stephen / Sha, Sharon J / Turner, Raymond S / Wingo, Thomas S / Wolk, David A / Womack, Kyle B / Carrillo, Maria C / Dickerson, Bradford C / Rabinovici, Gil D / Apostolova, Liana G

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2023  Volume 19 Suppl 9, Page(s) S115–S125

    Abstract: Introduction: One goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early-onset Alzheimer's disease (EOAD).: Methods: Cerebrospinal fluid (CSF) concentrations of Aβ1-40, Aβ1-42, ...

    Abstract Introduction: One goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early-onset Alzheimer's disease (EOAD).
    Methods: Cerebrospinal fluid (CSF) concentrations of Aβ1-40, Aβ1-42, total tau (tTau), pTau181, VILIP-1, SNAP-25, neurogranin (Ng), neurofilament light chain (NfL), and YKL-40 were measured by immunoassay in 165 LEADS participants. The associations of biomarker concentrations with diagnostic group and standard cognitive tests were evaluated.
    Results: Biomarkers were correlated with one another. Levels of CSF Aβ42/40, pTau181, tTau, SNAP-25, and Ng in EOAD differed significantly from cognitively normal and early-onset non-AD dementia; NfL, YKL-40, and VILIP-1 did not. Across groups, all biomarkers except SNAP-25 were correlated with cognition. Within the EOAD group, Aβ42/40, NfL, Ng, and SNAP-25 were correlated with at least one cognitive measure.
    Discussion: This study provides a comprehensive analysis of CSF biomarkers in sporadic EOAD that can inform EOAD clinical trial design.
    MeSH term(s) Humans ; Alzheimer Disease/diagnosis ; Alzheimer Disease/cerebrospinal fluid ; Chitinase-3-Like Protein 1 ; Amyloid beta-Peptides/cerebrospinal fluid ; tau Proteins/cerebrospinal fluid ; Longitudinal Studies ; Biomarkers/cerebrospinal fluid ; Neurogranin/cerebrospinal fluid
    Chemical Substances Chitinase-3-Like Protein 1 ; Amyloid beta-Peptides ; tau Proteins ; Biomarkers ; Neurogranin (132654-77-4)
    Language English
    Publishing date 2023-07-25
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.13399
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort.

    Nudelman, Kelly N H / Jackson, Trever / Rumbaugh, Malia / Eloyan, Ani / Abreu, Marco / Dage, Jeffrey L / Snoddy, Casey / Faber, Kelley M / Foroud, Tatiana / Hammers, Dustin B / Taurone, Alexander / Thangarajah, Maryanne / Aisen, Paul / Beckett, Laurel / Kramer, Joel / Koeppe, Robert / Kukull, Walter A / Murray, Melissa E / Toga, Arthur W /
    Vemuri, Prashanthi / Atri, Alireza / Day, Gregory S / Duara, Ranjan / Graff-Radford, Neill R / Honig, Lawrence S / Jones, David T / Masdeu, Joseph C / Mendez, Mario / Musiek, Erik / Onyike, Chiadi U / Riddle, Meghan / Rogalski, Emily / Salloway, Stephen / Sha, Sharon J / Turner, R Scott / Wingo, Thomas S / Wolk, David A / Carrillo, Maria C / Dickerson, Bradford C / Rabinovici, Gil D / Apostolova, Liana G

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2023  Volume 19 Suppl 9, Page(s) S64–S73

    Abstract: Introduction: One goal of the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is to investigate the genetic etiology of early onset (40-64 years) cognitive impairment. Toward this goal, LEADS participants are screened for known pathogenic ... ...

    Abstract Introduction: One goal of the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is to investigate the genetic etiology of early onset (40-64 years) cognitive impairment. Toward this goal, LEADS participants are screened for known pathogenic variants.
    Methods: LEADS amyloid-positive early-onset Alzheimer's disease (EOAD) or negative early-onset non-AD (EOnonAD) cases were whole exome sequenced (N = 299). Pathogenic variant frequency in APP, PSEN1, PSEN2, GRN, MAPT, and C9ORF72 was assessed for EOAD and EOnonAD. Gene burden testing was performed in cases compared to similar-age cognitively normal controls in the Parkinson's Progression Markers Initiative (PPMI) study.
    Results: Previously reported pathogenic variants in the six genes were identified in 1.35% of EOAD (3/223) and 6.58% of EOnonAD (5/76). No genes showed enrichment for carriers of rare functional variants in LEADS cases.
    Discussion: Results suggest that LEADS is enriched for novel genetic causative variants, as previously reported variants are not observed in most cases.
    Highlights: Sequencing identified eight cognitively impaired pathogenic variant carriers. Pathogenic variants were identified in PSEN1, GRN, MAPT, and C9ORF72. Rare variants were not enriched in APP, PSEN1/2, GRN, and MAPT. The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a key resource for early-onset Alzheimer's genetic research.
    MeSH term(s) Humans ; Alzheimer Disease/genetics ; Amyloid beta-Protein Precursor/genetics ; C9orf72 Protein/genetics ; Genetic Testing ; Longitudinal Studies ; Mutation ; Presenilin-1/genetics ; Presenilin-2/genetics
    Chemical Substances Amyloid beta-Protein Precursor ; C9orf72 Protein ; Presenilin-1 ; Presenilin-2
    Language English
    Publishing date 2023-10-06
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.13482
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Asian Cohort for Alzheimer's Disease (ACAD) pilot study on genetic and non-genetic risk factors for Alzheimer's disease among Asian Americans and Canadians.

    Ho, Pei-Chuan / Yu, Wai Haung / Tee, Boon Lead / Lee, Wan-Ping / Li, Clara / Gu, Yian / Yokoyama, Jennifer S / Reyes-Dumeyer, Dolly / Choi, Yun-Beom / Yang, Hyun-Sik / Vardarajan, Badri N / Tzuang, Marian / Lieu, Kevin / Lu, Anna / Faber, Kelley M / Potter, Zoë D / Revta, Carolyn / Kirsch, Maureen / McCallum, Jake /
    Mei, Diana / Booth, Briana / Cantwell, Laura B / Chen, Fangcong / Chou, Sephera / Clark, Dewi / Deng, Michelle / Hong, Ting Hei / Hwang, Ling-Jen / Jiang, Lilly / Joo, Yoonmee / Kang, Younhee / Kim, Ellen S / Kim, Hoowon / Kim, Kyungmin / Kuzma, Amanda B / Lam, Eleanor / Lanata, Serggio C / Lee, Kunho / Li, Donghe / Li, Mingyao / Li, Xiang / Liu, Chia-Lun / Liu, Collin / Liu, Linghsi / Lupo, Jody-Lynn / Nguyen, Khai / Pfleuger, Shannon E / Qian, James / Qian, Winnie / Ramirez, Veronica / Russ, Kristen A / Seo, Eun Hyun / Song, Yeunjoo E / Tartaglia, Maria Carmela / Tian, Lu / Torres, Mina / Vo, Namkhue / Wong, Ellen C / Xie, Yuan / Yau, Eugene B / Yi, Isabelle / Yu, Victoria / Zeng, Xiaoyi / St George-Hyslop, Peter / Au, Rhoda / Schellenberg, Gerard D / Dage, Jeffrey L / Varma, Rohit / Hsiung, Ging-Yuek R / Rosen, Howard / Henderson, Victor W / Foroud, Tatiana / Kukull, Walter A / Peavy, Guerry M / Lee, Haeok / Feldman, Howard H / Mayeux, Richard / Chui, Helena / Jun, Gyungah R / Ta Park, Van M / Chow, Tiffany W / Wang, Li-San

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2024  Volume 20, Issue 3, Page(s) 2058–2071

    Abstract: Introduction: Clinical research in Alzheimer's disease (AD) lacks cohort diversity despite being a global health crisis. The Asian Cohort for Alzheimer's Disease (ACAD) was formed to address underrepresentation of Asians in research, and limited ... ...

    Abstract Introduction: Clinical research in Alzheimer's disease (AD) lacks cohort diversity despite being a global health crisis. The Asian Cohort for Alzheimer's Disease (ACAD) was formed to address underrepresentation of Asians in research, and limited understanding of how genetics and non-genetic/lifestyle factors impact this multi-ethnic population.
    Methods: The ACAD started fully recruiting in October 2021 with one central coordination site, eight recruitment sites, and two analysis sites. We developed a comprehensive study protocol for outreach and recruitment, an extensive data collection packet, and a centralized data management system, in English, Chinese, Korean, and Vietnamese.
    Results: ACAD has recruited 606 participants with an additional 900 expressing interest in enrollment since program inception.
    Discussion: ACAD's traction indicates the feasibility of recruiting Asians for clinical research to enhance understanding of AD risk factors. ACAD will recruit > 5000 participants to identify genetic and non-genetic/lifestyle AD risk factors, establish blood biomarker levels for AD diagnosis, and facilitate clinical trial readiness.
    Highlights: The Asian Cohort for Alzheimer's Disease (ACAD) promotes awareness of under-investment in clinical research for Asians. We are recruiting Asian Americans and Canadians for novel insights into Alzheimer's disease. We describe culturally appropriate recruitment strategies and data collection protocol. ACAD addresses challenges of recruitment from heterogeneous Asian subcommunities. We aim to implement a successful recruitment program that enrolls across three Asian subcommunities.
    MeSH term(s) Humans ; Alzheimer Disease/genetics ; Pilot Projects ; Asian/genetics ; Canada ; Risk Factors ; North American People
    Language English
    Publishing date 2024-01-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.13611
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Analysis of copy number variation in Alzheimer's disease: the NIALOAD/ NCRAD Family Study.

    Swaminathan, Shanker / Shen, Li / Kim, Sungeun / Inlow, Mark / West, John D / Faber, Kelley M / Foroud, Tatiana / Mayeux, Richard / Saykin, Andrew J

    Current Alzheimer research

    2011  Volume 9, Issue 7, Page(s) 801–814

    Abstract: Copy number variants (CNVs) are DNA regions that have gains (duplications) or losses (deletions) of genetic material. CNVs may encompass a single gene or multiple genes and can affect their function. They are hypothesized to play an important role in ... ...

    Abstract Copy number variants (CNVs) are DNA regions that have gains (duplications) or losses (deletions) of genetic material. CNVs may encompass a single gene or multiple genes and can affect their function. They are hypothesized to play an important role in certain diseases. We previously examined the role of CNVs in late-onset Alzheimer's disease (AD) and mild cognitive impairment (MCI) using participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study and identified gene regions overlapped by CNVs only in cases (AD and/or MCI) but not in controls. Using a similar approach as ADNI, we investigated the role of CNVs using 794 AD and 196 neurologically evaluated control non-Hispanic Caucasian NIA-LOAD/NCRAD Family Study participants with DNA derived from blood/brain tissue. The controls had no family history of AD and were unrelated to AD participants. CNV calls were generated and analyzed after detailed quality review. 711 AD cases and 171 controls who passed all quality thresholds were included in case/control association analyses, focusing on candidate gene and genome-wide approaches. We identified genes overlapped by CNV calls only in AD cases but not controls. A trend for lower CNV call rate was observed for deletions as well as duplications in cases compared to controls. Gene-based association analyses confirmed previous findings in the ADNI study (ATXN1, HLA-DPB1, RELN, DOPEY2, GSTT1, CHRFAM7A, ERBB4, NRXN1) and identified a new gene (IMMP2L) that may play a role in AD susceptibility. Replication in independent samples as well as further analyses of these gene regions is warranted.
    MeSH term(s) Aged ; Aged, 80 and over ; Alzheimer Disease/genetics ; Apolipoproteins E/genetics ; Case-Control Studies ; Cognitive Dysfunction/genetics ; DNA Copy Number Variations ; European Continental Ancestry Group/genetics ; Female ; Gene Dosage ; Genetic Predisposition to Disease ; Genome-Wide Association Study ; Genotype ; Humans ; Male ; Polymorphism, Single Nucleotide
    Chemical Substances Apolipoproteins E
    Language English
    Publishing date 2011-09-15
    Publishing country United Arab Emirates
    Document type Journal Article ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2205170-3
    ISSN 1875-5828 ; 1567-2050
    ISSN (online) 1875-5828
    ISSN 1567-2050
    DOI 10.2174/156720512802455331
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.

    Hendrix, James A / Airey, David C / Britton, Angela / Burke, Anna D / Capone, George T / Chavez, Ronelyn / Chen, Jacqueline / Chicoine, Brian / Costa, Alberto C S / Dage, Jeffrey L / Doran, Eric / Esbensen, Anna / Evans, Casey L / Faber, Kelley M / Foroud, Tatiana M / Hart, Sarah / Haugen, Kelsey / Head, Elizabeth / Hendrix, Suzanne /
    Hillerstrom, Hampus / Kishnani, Priya S / Krell, Kavita / Ledesma, Duvia Lara / Lai, Florence / Lott, Ira / Ochoa-Lubinoff, Cesar / Mason, Jennifer / Nicodemus-Johnson, Jessie / Proctor, Nicholas Kyle / Pulsifer, Margaret B / Revta, Carolyn / Rosas, H Diana / Rosser, Tracie C / Santoro, Stephanie / Schafer, Kim / Scheidemantel, Thomas / Schmitt, Frederick / Skotko, Brian G / Stasko, Melissa R / Talboy, Amy / Torres, Amy / Wilmes, Kristi / Woodward, Jason / Zimmer, Jennifer A / Feldman, Howard H / Mobley, William

    Journal of clinical medicine

    2021  Volume 10, Issue 9

    Abstract: With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However, with longevity comes a very high risk of Alzheimer's disease (AD). The LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting ...

    Abstract With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However, with longevity comes a very high risk of Alzheimer's disease (AD). The LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting 270 adults with DS over the age of 25. The study is designed to characterize trajectories of change in DS-associated AD (DS-AD). The current study reports its cross-sectional analysis of the first 90 subjects enrolled. Plasma biomarkers phosphorylated tau protein (p-tau), neurofilament light chain (NfL), amyloid β peptides (Aβ
    Language English
    Publishing date 2021-04-28
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm10091907
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.

    Swaminathan, Shanker / Huentelman, Matthew J / Corneveaux, Jason J / Myers, Amanda J / Faber, Kelley M / Foroud, Tatiana / Mayeux, Richard / Shen, Li / Kim, Sungeun / Turk, Mari / Hardy, John / Reiman, Eric M / Saykin, Andrew J

    PloS one

    2012  Volume 7, Issue 12, Page(s) e50640

    Abstract: Copy number variations (CNVs) are genomic regions that have added (duplications) or deleted (deletions) genetic material. They may overlap genes affecting their function and have been shown to be associated with disease. We previously investigated the ... ...

    Abstract Copy number variations (CNVs) are genomic regions that have added (duplications) or deleted (deletions) genetic material. They may overlap genes affecting their function and have been shown to be associated with disease. We previously investigated the role of CNVs in late-onset Alzheimer's disease (AD) and mild cognitive impairment using Alzheimer's Disease Neuroimaging Initiative (ADNI) and National Institute of Aging-Late Onset AD/National Cell Repository for AD (NIA-LOAD/NCRAD) Family Study participants, and identified a number of genes overlapped by CNV calls. To confirm the findings and identify other potential candidate regions, we analyzed array data from a unique cohort of 1617 Caucasian participants (1022 AD cases and 595 controls) who were clinically characterized and whose diagnosis was neuropathologically verified. All DNA samples were extracted from brain tissue. CNV calls were generated and subjected to quality control (QC). 728 cases and 438 controls who passed all QC measures were included in case/control association analyses including candidate gene and genome-wide approaches. Rates of deletions and duplications did not significantly differ between cases and controls. Case-control association identified a number of previously reported regions (CHRFAM7A, RELN and DOPEY2) as well as a new gene (HLA-DRA). Meta-analysis of CHRFAM7A indicated a significant association of the gene with AD and/or MCI risk (P = 0.006, odds ratio = 3.986 (95% confidence interval 1.490-10.667)). A novel APP gene duplication was observed in one case sample. Further investigation of the identified genes in independent and larger samples is warranted.
    MeSH term(s) Alzheimer Disease/genetics ; Alzheimer Disease/pathology ; Case-Control Studies ; Cohort Studies ; DNA Copy Number Variations ; Genome-Wide Association Study ; Humans
    Language English
    Publishing date 2012-12-05
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0050640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA).

    Vardarajan, Badri N / Faber, Kelley M / Bird, Thomas D / Bennett, David A / Rosenberg, Roger / Boeve, Bradley F / Graff-Radford, Neill R / Goate, Alison M / Farlow, Martin / Sweet, Robert A / Lantigua, Rafael / Medrano, Martin Z / Ottman, Ruth / Schaid, Daniel J / Foroud, Tatiana M / Mayeux, Richard

    JAMA neurology

    2014  Volume 71, Issue 3, Page(s) 315–323

    Abstract: Importance: Late-onset Alzheimer disease (LOAD), defined as onset of symptoms after age 65 years, is the most common form of dementia. Few reports investigate incidence rates in large family-based studies in which the participants were selected for ... ...

    Abstract Importance: Late-onset Alzheimer disease (LOAD), defined as onset of symptoms after age 65 years, is the most common form of dementia. Few reports investigate incidence rates in large family-based studies in which the participants were selected for family history of LOAD.
    Objective: To determine the incidence rates of dementia and LOAD in unaffected members in the National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA) family studies.
    Design, setting, and participants: Families with 2 or more affected siblings who had a clinical or pathological diagnosis of LOAD were recruited as a part of the NIA-LOAD/NCRAD Family Study. A cohort of Caribbean Hispanics with familial LOAD was recruited in a different study at the Taub Institute for Research on Alzheimer's Disease and the Aging Brain in New York and from clinics in the Dominican Republic as part of the EFIGA study.
    Main outcomes and measures: Age-specific incidence rates of LOAD were estimated in the unaffected family members in the NIA-LOAD/NCRAD and EFIGA data sets. We restricted analyses to families with follow-up and complete phenotype information, including 396 NIA-LOAD/NCRAD and 242 EFIGA families. Among the 943 at-risk family members in the NIA-LOAD/NCRAD families, 126 (13.4%) developed dementia, of whom 109 (86.5%) met criteria for LOAD. Among 683 at-risk family members in the EFIGA families, 174 (25.5%) developed dementia during the study period, of whom 145 (83.3%) had LOAD.
    Results: The annual incidence rates of dementia and LOAD in the NIA-LOAD/NCRAD families per person-year were 0.03 and 0.03, respectively, in participants aged 65 to 74 years; 0.07 and 0.06, respectively, in those aged 75 to 84 years; and 0.08 and 0.07, respectively, in those 85 years or older. Incidence rates in the EFIGA families were slightly higher, at 0.03 and 0.02, 0.06 and 0.05, 0.10 and 0.08, and 0.10 and 0.07, respectively, in the same age groups. Contrasting these results with the population-based estimates, the incidence was increased by 3-fold for NIA-LOAD/NCRAD families (standardized incidence ratio, 3.44) and 2-fold among the EFIGA compared with the NIA-LOAD/NCRAD families (1.71).
    Conclusions and relevance: The incidence rates for familial dementia and LOAD in the NIA-LOAD/NCRAD and EFIGA families are significantly higher than population-based estimates. The incidence rates in all groups increase with age. The higher incidence of LOAD can be explained by segregation of Alzheimer disease-related genes in these families or shared environmental risks.
    MeSH term(s) Age Factors ; Age of Onset ; Aged ; Aged, 80 and over ; Alzheimer Disease/epidemiology ; Alzheimer Disease/genetics ; Apolipoprotein E4/genetics ; Dominican Republic/epidemiology ; Female ; Follow-Up Studies ; Genetic Predisposition to Disease ; Humans ; Incidence ; Male ; National Institute on Aging (U.S.) ; New York/epidemiology ; United States/epidemiology
    Chemical Substances Apolipoprotein E4
    Language English
    Publishing date 2014-01-15
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2702023-X
    ISSN 2168-6157 ; 2168-6149
    ISSN (online) 2168-6157
    ISSN 2168-6149
    DOI 10.1001/jamaneurol.2013.5570
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top